PT3542817T - Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) - Google Patents
Anticorpos de neutralização do vírus de imunodeficiência humana (hiv)Info
- Publication number
- PT3542817T PT3542817T PT182077073T PT18207707T PT3542817T PT 3542817 T PT3542817 T PT 3542817T PT 182077073 T PT182077073 T PT 182077073T PT 18207707 T PT18207707 T PT 18207707T PT 3542817 T PT3542817 T PT 3542817T
- Authority
- PT
- Portugal
- Prior art keywords
- hiv
- immunodeficiency virus
- human immunodeficiency
- neutralizing antibodies
- neutralizing
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16101009P | 2009-03-17 | 2009-03-17 | |
| US16582909P | 2009-04-01 | 2009-04-01 | |
| US22473909P | 2009-07-10 | 2009-07-10 | |
| US28566409P | 2009-12-11 | 2009-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3542817T true PT3542817T (pt) | 2022-07-05 |
Family
ID=42668183
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT182077073T PT3542817T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
| PT107228108T PT2408476T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
| PT171948342T PT3323427T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
| PT171735483T PT3260136T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus da imunodeficiência humana (hiv) |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107228108T PT2408476T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
| PT171948342T PT3323427T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
| PT171735483T PT3260136T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus da imunodeficiência humana (hiv) |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US9051362B2 (pt) |
| EP (5) | EP2408476B1 (pt) |
| AU (5) | AU2010226668B2 (pt) |
| CA (2) | CA2980883C (pt) |
| CY (1) | CY1121323T1 (pt) |
| DK (1) | DK2408476T3 (pt) |
| ES (4) | ES2848555T3 (pt) |
| HR (1) | HRP20180027T1 (pt) |
| HU (1) | HUE036031T2 (pt) |
| LT (1) | LT2408476T (pt) |
| NO (1) | NO2408476T3 (pt) |
| PL (4) | PL2408476T3 (pt) |
| PT (4) | PT3542817T (pt) |
| SI (4) | SI3260136T1 (pt) |
| WO (1) | WO2010107939A2 (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53347B (en) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | TOLL-SIMILAR RECEPTOR MODULATORS |
| US20110212106A1 (en) * | 2010-01-20 | 2011-09-01 | Institute For Research In Bioscience | Hiv-1 neutralizing antibodies and uses thereof |
| CA2789483A1 (en) * | 2010-03-02 | 2011-09-09 | International Aids Vaccine Initiative | Novel hiv-1 envelope glycoprotein |
| EP4226935A3 (en) | 2010-08-31 | 2023-09-06 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
| ES2618380T3 (es) | 2010-09-24 | 2017-06-21 | International Aids Vaccine Initiative | Novedosos anticuerpos con amplio poder neutralizante de VIH-1 |
| EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
| US10040826B2 (en) | 2011-07-05 | 2018-08-07 | Duke University | Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens |
| US8791108B2 (en) * | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US20140348865A1 (en) | 2011-09-12 | 2014-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. | Immunogens based on an hiv-1 v1v2 site-of-vulnerability |
| EP2763699A4 (en) | 2011-10-03 | 2015-05-20 | Univ Duke | VACCINE |
| EP2788026A4 (en) | 2011-12-05 | 2015-08-05 | Univ Duke | V1V2 IMMUNOGENIC |
| CN104271597B (zh) | 2011-12-08 | 2018-05-25 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
| US20150044137A1 (en) * | 2012-03-23 | 2015-02-12 | The United States of America, as represented by the Secretary, Dep. of Health Care Human Services | Neutralizing antibodies to hiv-1 and their use |
| EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
| WO2014134547A1 (en) * | 2013-02-28 | 2014-09-04 | Therabiol, Inc. | Hiv antigens and antibodies |
| EP3010549A4 (en) * | 2013-06-17 | 2017-03-15 | Emory University | Pathogen binding agents conjugated to radioisotopes and uses in imaging and therapeutic applications |
| WO2015048517A1 (en) * | 2013-09-28 | 2015-04-02 | Duke University | Escape mutants |
| WO2015127108A1 (en) * | 2014-02-19 | 2015-08-27 | Duke University | Trimeric hiv-1 envelopes compositions and uses thereof |
| US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
| PL3166607T3 (pl) | 2014-07-11 | 2023-02-20 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych do leczenia hiv |
| JP2017526730A (ja) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体モジュレーターの固体形態 |
| WO2016054023A1 (en) * | 2014-09-29 | 2016-04-07 | Duke University | Hiv-1 antibodies and uses thereof (adcc and bispecific abs) |
| MA42818A (fr) | 2015-09-15 | 2018-07-25 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
| JP6955487B2 (ja) * | 2015-09-24 | 2021-10-27 | アブビトロ， エルエルシー | Ｈｉｖ抗体組成物および使用方法 |
| SG11201804787UA (en) | 2015-12-15 | 2018-07-30 | Gilead Sciences Inc | Human immunodeficiency virus neutralizing antibodies |
| CN107022027B (zh) * | 2016-02-02 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| CN107033241B (zh) * | 2016-02-03 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| KR102324568B1 (ko) | 2017-06-21 | 2021-11-10 | 길리애드 사이언시즈, 인코포레이티드 | HIV gp120 및 CD3을 표적화하는 다중특이적 항체 |
| WO2018237357A1 (en) * | 2017-06-22 | 2018-12-27 | University Of Maryland, Baltimore | HIV-LARGE SPECTRUM HIV NEUTRALIZATION ANTIBODIES AGAINST HIV |
| EP4257600A3 (en) | 2018-07-03 | 2024-01-10 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
| US20220227845A1 (en) * | 2018-10-19 | 2022-07-21 | University Of Maryland, College Park | Multispecific Anti-HIV Antibodies |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| CN115379856A (zh) * | 2019-10-29 | 2022-11-22 | 国际艾滋病疫苗行动组织 | HIV Env的工程化抗体 |
| WO2021183556A1 (en) * | 2020-03-09 | 2021-09-16 | Adma Biologics, Inc. | Immunotherapeutic compositions and methods of production for coronavirus |
| IL300256A (en) | 2020-08-25 | 2023-03-01 | Gilead Sciences Inc | Multispecific Antigen Binding Molecules Targeting HIV and Methods of Use |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022162009A1 (en) | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
| WO2022161597A1 (en) * | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
| WO2022225875A1 (en) * | 2021-04-19 | 2022-10-27 | The Wistar Institute Of Anatomy And Biology | Sialydase linked hiv antibodies and methods of use |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| EP0547065B1 (en) | 1990-06-29 | 2001-08-29 | Large Scale Biology Corporation | Melanin production by transformed microorganisms |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ES2165851T3 (es) | 1991-11-25 | 2002-04-01 | Enzon Inc | Proteinas multivalentes que se unen a antigenos. |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| EP1241264A1 (en) | 1994-12-02 | 2002-09-18 | Chiron Corporation | Monoclonal antibodies to colon cancer antigen |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
| AU2004204462B2 (en) | 2003-01-09 | 2012-03-08 | Macrogenics, Inc. | Dual expression vector system for antibody expression in bacterial and mammalian cells |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| CA2585574A1 (en) * | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
| EP4226935A3 (en) * | 2010-08-31 | 2023-09-06 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
-
2010
- 2010-03-01 SI SI201032049T patent/SI3260136T1/sl unknown
- 2010-03-17 EP EP10722810.8A patent/EP2408476B1/en active Active
- 2010-03-17 PL PL10722810T patent/PL2408476T3/pl unknown
- 2010-03-17 EP EP22171792.9A patent/EP4085925A1/en active Pending
- 2010-03-17 PT PT182077073T patent/PT3542817T/pt unknown
- 2010-03-17 ES ES17173548T patent/ES2848555T3/es active Active
- 2010-03-17 ES ES10722810.8T patent/ES2656234T3/es active Active
- 2010-03-17 EP EP17173548.3A patent/EP3260136B1/en active Active
- 2010-03-17 EP EP18207707.3A patent/EP3542817B1/en active Active
- 2010-03-17 SI SI201031616T patent/SI2408476T1/en unknown
- 2010-03-17 US US12/726,245 patent/US9051362B2/en active Active
- 2010-03-17 EP EP17194834.2A patent/EP3323427B1/en active Active
- 2010-03-17 LT LTEP10722810.8T patent/LT2408476T/lt unknown
- 2010-03-17 CA CA2980883A patent/CA2980883C/en active Active
- 2010-03-17 AU AU2010226668A patent/AU2010226668B2/en active Active
- 2010-03-17 PT PT107228108T patent/PT2408476T/pt unknown
- 2010-03-17 PL PL17194834T patent/PL3323427T3/pl unknown
- 2010-03-17 NO NO10722810A patent/NO2408476T3/no unknown
- 2010-03-17 DK DK10722810.8T patent/DK2408476T3/en active
- 2010-03-17 PL PL18207707.3T patent/PL3542817T3/pl unknown
- 2010-03-17 PT PT171948342T patent/PT3323427T/pt unknown
- 2010-03-17 SI SI201032062T patent/SI3323427T1/sl unknown
- 2010-03-17 WO PCT/US2010/027695 patent/WO2010107939A2/en active Application Filing
- 2010-03-17 SI SI201032112T patent/SI3542817T1/sl unknown
- 2010-03-17 ES ES17194834T patent/ES2848203T3/es active Active
- 2010-03-17 ES ES18207707T patent/ES2916404T3/es active Active
- 2010-03-17 CA CA2755821A patent/CA2755821C/en active Active
- 2010-03-17 HU HUE10722810A patent/HUE036031T2/hu unknown
- 2010-03-17 PT PT171735483T patent/PT3260136T/pt unknown
- 2010-03-17 PL PL17173548T patent/PL3260136T3/pl unknown
-
2015
- 2015-04-21 US US14/692,483 patent/US9920111B2/en active Active
- 2015-10-01 AU AU2015234345A patent/AU2015234345C1/en active Active
-
2017
- 2017-11-20 AU AU2017264985A patent/AU2017264985B2/en active Active
-
2018
- 2018-01-08 HR HRP20180027TT patent/HRP20180027T1/hr unknown
- 2018-01-15 CY CY20181100043T patent/CY1121323T1/el unknown
- 2018-03-12 US US15/918,343 patent/US10239934B2/en active Active
-
2019
- 2019-02-14 US US16/275,936 patent/US10407493B2/en active Active
- 2019-07-17 US US16/513,859 patent/US10865234B2/en active Active
-
2020
- 2020-07-30 AU AU2020210242A patent/AU2020210242B2/en active Active
- 2020-10-28 US US17/082,322 patent/US11584789B2/en active Active
-
2023
- 2023-01-06 US US18/150,957 patent/US12018067B2/en active Active
- 2023-06-26 AU AU2023204017A patent/AU2023204017A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE036031T2 (hu) | Humán immundeficiencia vírus (HIV) semlegesítõ ellenanyagok | |
| AU2016202543A1 (en) | Human immunodeficiency virus (hiv)-neutralizing antibodies | |
| EP2611465A4 (en) | NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV) | |
| HK1212935A1 (zh) | 廣譜中和抗 抗體 | |
| AP2011005944A0 (en) | Inhibitors of human immunodeficiency virus replication. | |
| EP2380976A4 (en) | HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS | |
| PT3494972T (pt) | Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv | |
| DK3329772T3 (da) | Dobbeltvektor til inhibering af human immundefektvirus | |
| ZA201202116B (en) | Neutralizing antibodies to hiv-1 and their use | |
| EP2618843A4 (en) | NEW ANTIBODIES WITH EXCESSIVE HIV-1 NEUTRALIZATION | |
| EP2542703A4 (en) | NEW HIV-1 ENVELOPE GLYCOPROTEIN | |
| ZA201002445B (en) | Hiv preventive vaccine based on hiv specific antibodies | |
| ZA201207030B (en) | Hiv vaccine | |
| IL212311A0 (en) | Immunoenhancer-linked oligomeric hiv vaccines | |
| EP2571523A4 (en) | REACTIVATION OF THE HUMAN IMMUNODEFICIENCY VIRUS IN THE LATENT STATE | |
| AP2013007180A0 (en) | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto | |
| EP2635300A4 (en) | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV) | |
| GB0912950D0 (en) | Virus | |
| EP2542252A4 (en) | HIV-1 CASE-BASED FRAGMENTS | |
| ZA201302639B (en) | Antibodies for the treatment of hiv | |
| PT2643460T (pt) | Métodos, composições e kits para determinação do virus da imunodeficiência humana (vih) | |
| ZA201105357B (en) | Splitting gp41 | |
| GB0901056D0 (en) | Virus | |
| HK1177692A1 (zh) | 新的流感病毒 | |
| AP3595A (en) | Novel gp41 antigens |